Fluorodeoxyglucose Positron Emission Tomography in Richardson’s Syndrome and Progressive (CROSBI ID 174352)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Srulijes, Karin ; Reimold, Matthias ; Liščić, Rajka M. ; Bauer, Sarah ; Dietzel, Elisabeth ; Liepelt-Scarfone, Inga ; Berg, Daniela ; Maetzler, Walter
engleski
Fluorodeoxyglucose Positron Emission Tomography in Richardson’s Syndrome and Progressive
Background: We hypothesized that postural instability and cognitive decline in patients with Richardson’s syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson’s disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose-PET. Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson’s disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson’s syndrome patients. Conclusion: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson’s disease showed different metabolic patterns in fluorodeoxyglucose-PET.
Richardson´s syndrome; Progressive supranuclear palsy
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti